CAPSULE SUMMARY
neurological disease, ±, hyperlipidaemia, skin erythema, itching, redness, hypertension, diabetes
NEUROLOGICAL DISEASE, CARDIOVASCULAR DISEASES, SEBORRHEIC DERMATITIS, HYPERLIPIDAEMIA, SKIN ERYTHEMA, MULTIPLE SCLEROSIS (MS), THYROID DISEASES, SKIN CONDITION, SEBORRHEIC DERMATITIS, HYPERTENSION, DISEASES, DIABETES

Seborrheic dermatitis is a common skin condition characterised by itching, redness and scaling on the head, face and chest areas. To date, numerous systemic and local treatments have been proposed for this condition, with varying degrees of improvement and relapse. On the other hand, the injection of botulinum toxin has many applications in dermatology, for example, to improve wrinkles, to control excessive sweating and so on. As for the role of botulinum toxin injection in controlling the symptoms of seborrheic dermatitis, the results of previous studies are contradictory.
This prospective, single‐arm clinical trial examined patients who presented symptoms of seborrheic dermatitis when referred for botulinum toxin injection to control skin wrinkles. The study aimed to assess the improvement in seborrheic dermatitis symptoms after the injection of botulinum toxin, and the results showed a decrease in severity indicators during the 1‐month follow‐up period. However, this difference was not statistically significantGender distribution chart of patients.The average age of the patients was 40.05 (±11.56) years, of which the youngest patient was 26 years old and the oldest patient was 67 years old. Patients were divided into 4 age groups and the highest frequency was in the age group of 26–37 years with 55%. The frequency and percentage distribution of patients in different age ranges can be seen in Table Distribution table of the frequency of patients in different age ranges.The most frequent underlying diseases were diabetes, hypertension and cardiovascular diseases each with two people (10%) of the patients, followed by thyroid diseases, hyperlipidaemia and neurological diseases with 1 person each (5%) of the patients. The only neurological disease detected in the patients' records was multiple sclerosis (MS). Figure Distribution chart of the frequency of underlying diseases among the patients.The drugs used by the investigated patients included metformin, insulin, levothyroxine, losartan and atorvastatin, each with a frequency of 1 person (5%).There was a history of receiving botulinum toxin in 11 patients (55%) and the average number of times of receiving botulinum toxin among patients was calculated to be 1.4 ± 1.67 times.Tables The table of average scores obtained from the studied criteria based on SDASI between patients at the first visit and 1 month after botulinum toxin injection in the scalp.The table of average scores obtained from the studied criteria based on SDASI between patients at the first visit and 1 month after botulinum toxin injection in the facial skin.The average of all criteria was associated with a decrease in the Likert scale number in the assessment one month after injection, but this decrease was not a statistically significant change in any of the criteria (In the evaluation of the scalp, despite the decrease in the average scores, in all measures of severity and extent of lesions; in none of the measures of skin erythema (The overall severity of seborrheic dermatitis in the scalp 1 month after Botox injection compared to the first visit, despite the average decrease from 7.7 (±7.15) to 6.6 (±6.76), there was no statistically significant difference (The average of all criteria was associated with a decrease in the Likert scale number in the assessment 1 month after injection, but this decrease was not a statistically significant change in any of the criteria (In the evaluation of the scalp, despite the decrease in the average scores, in all measures of severity and extent of lesions; in none of the measures of skin erythema (The overall severity of seborrheic dermatitis in the scalp one month after Botox injection compared to the first visit, despite the average decrease from 7.7 (±7.15) to 6.6 (±6.76), there was no statistically significant difference (The chart of comparison between average scores of seborrheic dermatitis severity in the scalp at the first visit and one month after botulinum toxin injection.In the evaluation of the facial skin, despite the decrease in the average scores in all criteria of intensity and extent of lesions, in none of the criteria of skin erythema (The overall severity of seborrheic dermatitis in the facial skin one month after botulinum toxin injection compared to the first visit, despite the decrease of the average from 4.05 (±4.55) to 3.45 (±4.55), there was no statistically significant difference (The chart of comparison of average scores of seborrheic dermatitis severity in the facial skin at the first visit and one month after botulinum toxin injection.